Xenon Pharmaceuticals (XENE) Cash from Investing Activities (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Cash from Investing Activities data on file, last reported at -$407.3 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 1280.19% year-over-year to -$407.3 million in Q1 2026; TTM through Mar 2026 was -$223.8 million, a 192.21% decrease from a year earlier, with the FY2025 full-year figure at $218.0 million, up 32.12% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$407.3 million, down from $62.7 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for XENE reached as high as $109.2 million in Q2 2024 and fell as low as -$407.3 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$25.2 million across 5 years, with a median of $27.9 million in 2023.
• Across the five-year window, Cash from Investing Activities sank 1943.03% in 2023 and soared 7637.15% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$11.7 million in 2022, then sank by 1943.03% to -$239.8 million in 2023, then jumped by 141.08% to $98.5 million in 2024, then sank by 36.35% to $62.7 million in 2025, then slumped by 749.6% to -$407.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$407.3 million in Q1 2026, $62.7 million in Q4 2025, and $38.5 million in Q3 2025.